See more : JPY/KMF (7NR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Revive Therapeutics Ltd. (RVV.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Revive Therapeutics Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- WHA Industrial Leasehold Real Estate Investment Trust (WHAIR.BK) Income Statement Analysis – Financial Results
- Lebledor F&B Co., Ltd. (7757.TWO) Income Statement Analysis – Financial Results
- Kunming Dianchi Water Treatment Co., Ltd. (3768.HK) Income Statement Analysis – Financial Results
- Chow Tai Fook Jewellery Group Limited (1929.HK) Income Statement Analysis – Financial Results
- AoFrio Limited (AOF.NZ) Income Statement Analysis – Financial Results
Revive Therapeutics Ltd. (RVV.CN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.revivethera.com
About Revive Therapeutics Ltd.
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 328.00 | 434.00 | 578.00 | 775.00 | 28.27K | 3.20K | 3.13K | 3.57K | 6.22K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -328.00 | -434.00 | -578.00 | -775.00 | -28.27K | -3.20K | -3.13K | -3.57K | -6.22K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.11M | 3.58M | 15.16M | 6.70M | 455.09K | 124.81K | 373.19K | 408.22K | 1.57M | 747.56K | 164.64K | 64.23K |
| General & Administrative | 0.00 | 1.62M | 2.67M | 11.61M | 3.20M | 1.19M | 1.47M | 1.26M | 1.12M | 1.26M | 739.29K | 127.26K |
| Selling & Marketing | 0.00 | 313.64K | 8.22K | 275.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.18M | 1.94M | 2.68M | 11.89M | 3.20M | 1.19M | 1.47M | 1.26M | 1.12M | 1.26M | 739.29K | 127.26K |
| Other Expenses | 0.00 | 0.00 | 578.00 | 775.00 | 28.27K | 3.20K | 3.13K | 3.57K | 6.22K | 6.59K | 4.35K | 0.00 |
| Operating Expenses | 3.29M | 5.52M | 17.83M | 18.59M | 3.68M | 1.32M | 1.84M | 1.67M | 2.70M | 2.02M | 908.28K | 193.39K |
| Cost & Expenses | 3.29M | 5.52M | 17.83M | 18.59M | 3.68M | 1.32M | 1.84M | 1.67M | 2.70M | 2.02M | 908.28K | 193.39K |
| Interest Income | 61.98K | 71.79K | 123.16K | 103.08K | 48.65K | 6.03K | 4.45K | 0.00 | 7.91K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 23.29K | 44.00K | 63.42K | 78.98K | 87.66K | 2.54K | 2.72K | 0.00 | 1.05K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 328.00 | 434.00 | 578.00 | 775.00 | 28.27K | 3.20K | 3.13K | 3.57K | 6.22K | 6.59K | 4.35K | 1.91K |
| EBITDA | -5.60M | -5.52M | -17.74M | -18.57M | -5.26M | -1.31M | -1.84M | -1.67M | -2.69M | -2.02M | -903.94K | -191.49K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.29M | -5.41M | -17.72M | -18.50M | -4.84M | -1.32M | -1.90M | -1.68M | -2.70M | -2.03M | -908.28K | -193.39K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.33M | -796.15K | 32.46K | -1.55M | -1.72M | -30.59K | 48.80K | 56.11K | -40.33K | -21.78K | -348.81K | 0.00 |
| Income Before Tax | -5.62M | -6.32M | -17.81M | -20.12M | -5.38M | -1.34M | -1.79M | -1.62M | -2.74M | -2.03M | -1.26M | -193.39K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.31M | 44.00K | 26.70K | 78.98K | -1.12M | 27.39K | -108.31K | -115.71K | 80.65K | 30.38K | 697.61K | 0.00 |
| Net Income | -5.62M | -6.32M | -17.83M | -20.20M | -4.27M | -1.37M | -1.68M | -1.62M | -2.74M | -2.03M | -1.26M | -193.39K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.02 | -0.06 | -0.08 | -0.04 | -0.02 | -0.03 | -0.03 | -0.11 | -0.09 | -0.06 | -0.02 |
| EPS Diluted | -0.01 | -0.02 | -0.06 | -0.08 | -0.04 | -0.02 | -0.03 | -0.03 | -0.11 | -0.09 | -0.06 | -0.02 |
| Weighted Avg Shares Out | 380.48M | 339.37M | 319.76M | 267.49M | 106.88M | 63.97M | 55.87M | 47.69M | 24.24M | 21.55M | 20.41M | 11.76M |
| Weighted Avg Shares Out (Dil) | 380.48M | 339.37M | 319.76M | 267.49M | 106.88M | 63.97M | 55.87M | 47.69M | 24.24M | 21.55M | 20.41M | 11.76M |
Source: https://incomestatements.info
Category: Stock Reports